LIM2551

Human derived from an adenocarcinoma of the transverse colon

LIM2551 was derived from an adenocarcinoma of the transverse colon. Cell Bank Australia reference number: CBA0170.

Not specified

RPMI 1640 (R0883) (with 2 mM L-Glutamine (G7513) + 25mM HEPES) + FBS / FCS (F2442), Insulin 0.6 μg/ml, Hydrocortisone 1 μg/ml, 1-Thioglycerol 10 μM.

Optimal split ratio 1:8-1:16 (seeding density 1 x 10⁴ cells/cm²). Cells incubated at 37 °C with 5% CO₂. Harvest the cells using 0.05% Trypsin/EDTA at 37 °C for 5 min. LIM2551 requires the growth medium to be changed 3 times each week. Feed and passage as for semi-adherent culture (collect medium with floating cells and then trypsinise the adherent population, pool both together before reseeding).

Additional freight & handling charges may be applicable for Asia-Pacific shipments.  Please check with your local Customer Service representative for more information.

Cultures from HPA Culture Collections and supplied by Sigma are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.

Depositor and originator: Professor Tony Burgess - Ludwig Institute for Cancer Research Ltd, Melbourne, Australia

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.